Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Loading ETF research
Fetching the latest fund profile, holdings, and market data.
New York Stock Exchange ArcaEquity
Previous close
$124.09
−$0.6464 · -0.52%
Sep 11, 3:59 PM ET
Regular session · ET · Market data may be delayed.
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Fund assets
544.86M USD
Expense ratio
0.58%
NAV
$124.11
Average volume
30.67K
Volume
26.4K
Day range
$124.03 – $125.99
52-week range
$90.01 – $131.68
Previous close
$124.74
Price change
1 day
-0.52%
1 month
-1.01%
3 months
+8.99%
Year to date
+18.70%
1 year
+36.50%
3 years
+61.34%
5 years
+57.20%
Price changes exclude distributions, fees, taxes, and investor-specific cash flows.
Portfolio
Holdings data updated Sep 13, 2026.
Portfolio composition
Fund income
Jun 22, 2026
Jun 22, 2026
Jun 26, 2026
$0.2733
Quarterly
Mar 23, 2026
Mar 23, 2026
Mar 27, 2026
$0.309
Quarterly
Dec 22, 2025
Dec 22, 2025
Dec 26, 2025
$0.2463
Quarterly
Sep 22, 2025
Sep 22, 2025
Sep 26, 2025
$0.2363
Quarterly
Jun 23, 2025
Jun 23, 2025
Jun 27, 2025
$0.2668
Quarterly
Mar 24, 2025
Mar 24, 2025
Mar 28, 2025
$0.2729
Quarterly
Dec 23, 2024
Dec 23, 2024
Dec 27, 2024
$0.2232
Quarterly
Sep 23, 2024
Sep 23, 2024
Sep 27, 2024
$0.2004
Quarterly
Jun 24, 2024
Jun 24, 2024
Jun 28, 2024
$0.2105
Quarterly
Mar 18, 2024
Mar 19, 2024
Mar 22, 2024
$0.1695
Quarterly
Latest coverage
More funds
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.
